Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
A patient with metastatic pancreatic cancer, ECOG performance status 2, and pre-existing neuropathy faces sequential treatment decisions. This interactive case examines tolerability, molecular findings, and safety counseling without implying that every detected alteration is actionable.
Medical Oncology November 11th 2026
Medical Xpress
Analysis of 189 colorectal tumors linked younger age to differences in stromal composition and gene activity. Additional datasets supported the stromal finding, but the study did not establish that these patterns cause aggressive disease.
Gastroenterology November 11th 2026
Oncology News Central (ONC)
In SAFFRON, median overall survival reached 17.8 months with dual EGFR/MET inhibition versus 12.9 months with chemotherapy. Results apply to patients with MET overexpression and/or amplification after osimertinib progression, not all EGFR-mutated NSCLC.
Practical Neurology
The revised McDonald criteria recognize the cerebrospinal fluid κFLC index as an alternative to oligoclonal bands for demonstrating intrathecal immunoglobulin synthesis, expanding laboratory options while preserving the need for integrated MS diagnosis.
Neuroimmunology October 22nd 2026
Tumor genomes may evolve during treatment as resistant subclones emerge under therapeutic pressure, prompting increasing use of comprehensive genomic profiling and serial ctDNA testing to inform ongoing precision oncology decisions.
Hematology/Oncology September 24th 2026
Clinical Advances in Hematology & Oncology
Artificial intelligence tools are increasingly being integrated into prostate cancer imaging, pathology, prognostication, and treatment planning. Although several platforms have demonstrated promising accuracy and workflow benefits, broad clinical adoption will require prospective validation, regulatory oversight, and careful implementation.
Health Informatics September 3rd 2026